TScan Therapeutics Inc. (NASDAQ: TCRX)
$7.10
+0.3600 ( +5.34% ) 235.4K
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Market Data
Open
$7.10
Previous close
$6.74
Volume
235.4K
Market cap
$375.33M
Day range
$6.76 - $7.18
52 week range
$1.93 - $9.69
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-k | Annual reports | 97 | Mar 06, 2024 |
8-k | 8K-related | 14 | Mar 06, 2024 |
4 | Insider transactions | 1 | Feb 02, 2024 |
3 | Insider transactions | 2 | Feb 02, 2024 |
8-k | 8K-related | 16 | Jan 29, 2024 |
4 | Insider transactions | 1 | Dec 21, 2023 |
4 | Insider transactions | 1 | Dec 18, 2023 |
8-k | 8K-related | 44 | Dec 11, 2023 |
4 | Insider transactions | 1 | Dec 08, 2023 |
3 | Insider transactions | 2 | Dec 08, 2023 |